Ask the Experts Webinar: Seizure or Senior Moments - The Nuances of Seizure Management in Late Onset Epilepsy

Join our presenter, Dr. Rebecca O'Dwyer, as we discuss epilepsy in older adults. Diagnosing and managing epilepsy in older adults can be challenging, particularly when seizure symptoms overlap with cognitive changes, syncope, sleep disorders, and other conditions commonly seen with aging. This webinar will explore the nuances of recognizing late-onset epilepsy and distinguishing seizures from potential mimics. Our expert will review approaches to developing individualized treatment plans that account for patient comorbidities, medication considerations, and quality-of-life needs. Attendees will also examine common treatment roadblocks and practical strategies for addressing challenges that may affect successful seizure management.

Presenter:

Rebecca O'Dwyer, MD

Rebecca O'Dwyer, MD graduated from Ludwigs Maximillian University, Munich Germany before completing her epilepsy fellowship at the Cleveland Clinic and her Neurology residency at Georgetown University. She specializes in epilepsy in older adults, and after completing a mini-fellowship in Geriatrics at UCLA founded one of the first comprehensive clinics for older adults with epilepsy in 2017 at Rush University, where she continues to practice. She has written extensively and given many national and international talks on epilepsy in this age group. She served as a member of the ILAE Task Force for Epilepsy in the Elderly and is currently a member of the ILAE Mature Brain and Epilepsy Commission's Post-Stroke Task Force. She chairs and is one of the founding members of the International Consortium of Clinics for oldEr adults with Epilepsy (ICCEE), participating in varied research across many borders and specialties.

Moderator:

Wajiha Yousuf, MD

At the end of this webinar, attendees should be able to:

Identify different seizure types and possible mimics
Develop treatment plans specific to patient and their comorbidities
Identify and develop strategies to manage treatment roadblocks

Disclosure Policy
It is the policy of the American Epilepsy Society (AES) to ensure balance, independence, objectivity and scientific rigor. All individuals involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. Conflicts of interest will be resolved by AES prior to an educational activity being delivered to learners.

Planning Committee, Faculty, Reviewers' Disclosures of Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, the AES requires that any person who is in a position to control content of a CME activity must disclose all relevant financial relationships that they have with an ineligible company. Unless otherwise indicated (*), none of the planners or faculty of this activity have any financial relationships to disclose. All relevant financial relationships with ineligible companies have been mitigated. The following individuals contributed to this activity's content. Update for all courses this year.

Planning Committee and Faculty
Wolfgang Muhlohofer, MD (Chair)
Jaysingh Singh, MD (Vice Chair)
Ruba Al-Ramadhani, MD
Evelyn Berman, MD
Jonathan Dashkoff, MD
Proleta Datta, MD
Alyssa Ho, MD
Matthew Hoerth, MD
Scheherazade Le, MD
Jose Montes-Rivera, MD
Georgios Ntolkeras, MD
Rebecca O'Dwyer, MD
Viktoras Palys, MD
Christopher Ryan
Priyanka Sabharwal, MD
Yash Shah
Aparna Vaddiparti
Lawrence Ver Hoef
Kristine Ziemba, MD

CME Reviewer
Shaharam Izadyar, MD, FAES

American Epilepsy Society Staff Planners
Melissa Ball, CAE, PMP

Resolution of Conflicts of Interest
It is the policy of the American Epilepsy Society to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. In accordance with the ACCME Standards for Commercial Support of CME, the AES implemented the mechanisms of prospective peer review of this CME activity, to identify and resolve any conflicts. Additionally, the content of this activity is based on the best available evidence.

Accreditation
The American Epilepsy Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

For more information regarding contact hours, please call American Epilepsy Society 312.883.3800 or education@aesnet.org.

Credit Designation
The American Epilepsy Society designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Certificate
To receive credit for your participation in this activity, please complete the evaluation survey provided at the conclusion of the activity.

Unapproved Use Disclosure
The American Epilepsy Society requires CME authors to disclose to learners when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. Information about pharmaceutical agents/devices that is outside of U.S. Food and Drug Administration approved labeling may be contained in this activity.

Disclaimer
This CME activity is for educational purposes only and does not constitute the opinion or endorsement of, or promotion by, the American Epilepsy Society. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label, investigational and/or experimental uses.